Our Cold Plasma Medical Device leads the way
Bacteria protected within biofilm are up to 1000x more resistant to antibiotics. This can complicate treatment options for wounds and surgical site infections but as it is an international form of therapy, it remains used throughout patient treatments despite it offering little to no help in healing problematic/stalled wounds and infections.
The cost burden associated to ongoing antibiotic therapy is significant as is the antimicrobial resistance rates that are ever growing. The World Health Organisation recognizes this and more hospitals are reaching out to alternative therapies to help curb the spending costs and antimicrobial resistance rates.
As the Adtec SteriPlas cold plasma has been shown to kill all forms of bacteria, regardless of their resistance profile or if they are Gram -ve or +ve or even if they are protected within biofilm, it has become widely adopted as an alternative to antibiotic therapy specifically in cases where patients are at a severe stage of infection such as those associated to diabetic foot ulcers and left ventricular assist device infections.
It has been praised as a life-saving medical device helping to heal infections that have been stalled for a very long time where conventional therapies have failed to act, reduce amputation and mortality rates.
This year we look forward to releasing a series of Health Economic publications documenting the cost effectiveness of our medical device against the use conventional therapies. We look forward to releasing this information to you in due time.
Until then, please reach out to us to learn more about why the interest in our medical device is growing daily. The data collection of our safety and efficacy shows why using an Adtec SteriPlas could completely change the way you treat patients.
The Safety and Reliability of our Cold Plasma
Is our cold plasma safe?
Yes!
As you can see from the photo, our Adtec technician demonstrates touching the cold plasma jet.
An extensive list of practical tests and experiments were conducted during our first stage, pre clinical studies and ongoing post-market studies. This allowed us to carefully develop a cold plasma medical device that could bring all the antibacterial benefits but at the same time remain painless and contact-free so that it could be well tolerated in patient treatments. We were after all the first company worldwide to introduce cold plasma treatment on wounds demonstrated in our clinical trials.
As cold plasma can be generated through a variety of ways, they are also dependent on the plasma source design and surrounding environment. The components of plasma include reactive oxygen and nitrogen species and UV that need to be controlled to ensure they are within safe levels for medical use. Some plasma devices may also deliver fluctuating inconsistent cold plasma output as they are sensitive to changes in humidity and temperature in the treatment room. This may often result in undesirable side effects.
Because the Adtec SteriPlas is a low energy, microwave-powered, cold atmospheric argon plasma medical device this means its safety remains the main priority in line with delivering repeatable and successful results. It is also the reason why we are proud to state our medical device has NO side effects associated to it.
Our patented 6 electrode Cold Plasma Torch
The Adtec SteriPlas features a patented 6 electrode cold plasma torch. It’s proven efficacy for the destruction of all forms of bacteria including multi-resistant bugs makes it an alternative to antibiotic therapy for the treatment of wounds, surgical site infections and medical dermatology skin conditions. This is due to the unique physical mode of action delivered with our cold plasma as opposed to the chemical mode of action demonstrated with antibiotics. Broader studies have shown that antimicrobial resistance is unlikely to be generated with cold plasma treatment because of this.
A huge collection of our peer reviewed publications documents the clinical efficacy and safety of our medical device across a broad range of conditions including diabetic foot ulcers, left ventricular assist device (LVAD) infections, deep sternal wound infections, actinic keratoses and acne.
To learn more about our medical device or to obtain one in your clinic practice, please contact us at info@adtecplasma.com
Adtec Healthcare's Conference and Exhibition attendance dates for 2022
As we look forward to a promising year ahead, please find the dates of our conference and exhibition participation for 2022:
Society for Cardiothoracic Surgery (SCTS) Annual Meeting – 8-10 May 2022
Malvern Diabetic Foot Conference – 11-13 May 2022
European Wound Management Association (EWMA) – 23-25 May 2022
Diabetic Foot Study Group (DFSG) – 16-18 September 2022
We hope to see you at either of these conferences and as always, we will have our flagship medical device, the Adtec SteriPlas, on demonstration ready for you to test and to see all the benefits linked to our cold plasma strengths for wounds, surgical site infections and medical dermatology.
The first cold plasma medical device to treat Scleroderma
We congratulate Dr Stephanie Ardnt and Prof. Sigrid Karrer from the University Hospital Regensburg for their recent publication, “The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo”.
This publication features the use of our Adtec SteriPlas and shows strong efficacy for the treatment of Scleroderma, which up to now has not yet been evaluated by CAP. The extensive study documents significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. This study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.
https://doi.org/10.3390/biomedicines9111545
Deep Sternal Wound Infections (DWSI) and the Adtec SteriPlas
Unlike other cold plasma medical devices currently present on the market, the Adtec SteriPlas is not limited to the treatment of superficial wounds only.
For example, deep sternal wound infections (DSWIs) are a potentially devastating complication of median sternotomy performed in cardiac surgery. These large wound cavities are prone to infections and there is a concerningly high morbidity and mortality rate associated to these patients. The use of conventional therapies alone has shown to not always be successful and expensive muscle flap surgery is usually required.
The large 12cm2 treatment area of the Adtec SteriPlas covers a greater surface area of the wound compared to its competitors. This allows the benefit of a quick 2 minute treatment time for every 12cm2 covered. Because of its propulsion towards the treatment site, the cold plasma components work quickly to defeat bacteria and allow the management of the infection. The use of the Adtec SteriPlas has shown to accelerate healing rates and prevent the need for expensive surgery options that would otherwise have been needed.
It has been praised as a lifesaving medical device and is now widely used across multiple hospitals for the management of DWSIs.
Quick results achieved with the Adtec SteriPlas
How often do LVAD patients with infection need treatment with the Adtec SteriPlas?
We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.
The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.
How quick have patients with LVAD infections healed?
Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.
E-poster at the EADV 2021 Conference
We look forward to supporting Fiona Koch’s e-poster that will be live during the EADV 2021 Spring Symposium tomorrow. Tune in to their website to get full access to her poster, “Efficacy of cold atmospheric plasma versus diclophenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP)”.
To learn more about the Adtec SteriPlas’ strong clinical efficacy for the treatment of actinic keratoses, contact us at info@adtecplasma.com
Deep Sternum Surgical Site Infections (DSSIs)
Deep sternal surgical site infections (DSSIs) are a still a severe complication after cardiac surgery. The mortality estimated range is between 15%-40% of all cases. In addition to the significantly extended hospitalization, there is a significant cost burden with a calculated cost of € 36,000 for a single DSSI case.
The use of the Adtec SteriPlas for these complicated conditions has been actively documented as better managing the chronic infections, reducing hospitalization times and cost but more importantly it has shown to decrease the mortality rate. Our medical device has been praised as a tissue and life saving medical device.
Herz medizin 2021
We look forward to supporting Dr Heinrich Rotering’s presentation, “Avoiding sternal wire removal in early onset of sternal site infection - Two years experience with an optimized treatment concept using cold atmospheric plasma“ at the Annual scientific meeting of the German Society for Thoracic, Cardiac and Vascular Surgery. His presentation will discuss the strong benefits of using the Adtec SteriPlas for complicated sternal wound infections in cardiac patients.
The conference will be held virtually between 26-28 February: https://www.dgthg.de/de/jahrestagung